Cargando…
Cardiac symptom burden and arrhythmia recurrence drives digital health use: results from the iHEART randomized controlled trial
AIMS: Digital health can transform the management of atrial fibrillation (AF) and enable patients to take a central role in detecting symptoms and self-managing AF. There is a gap in understanding factors that support sustained use of digital health tools for patients with AF. This study identified...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560656/ https://www.ncbi.nlm.nih.gov/pubmed/34009326 http://dx.doi.org/10.1093/eurjcn/zvab009 |
_version_ | 1784592962782494720 |
---|---|
author | Masterson Creber, Ruth M Reading Turchioe, Meghan Biviano, Angelo Caceres, Billy Garan, Hasan Goldenthal, Isaac Koleck, Theresa Mitha, Shazia Hickey, Kathleen Bakken, Suzanne |
author_facet | Masterson Creber, Ruth M Reading Turchioe, Meghan Biviano, Angelo Caceres, Billy Garan, Hasan Goldenthal, Isaac Koleck, Theresa Mitha, Shazia Hickey, Kathleen Bakken, Suzanne |
author_sort | Masterson Creber, Ruth M |
collection | PubMed |
description | AIMS: Digital health can transform the management of atrial fibrillation (AF) and enable patients to take a central role in detecting symptoms and self-managing AF. There is a gap in understanding factors that support sustained use of digital health tools for patients with AF. This study identified predictors of Alivecor(®) KardiaMobile ECG monitor usage among patients with AF enrolled in the iPhone(®)Helping Evaluate Atrial fibrillation Rhythm through Technology (iHEART) randomized controlled trial. METHODS AND RESULTS: We analysed data from 105 English and Spanish-speaking adults with AF enrolled in the intervention arm of the iHEART trial. The iHEART intervention included smartphone-based electrocardiogram self-monitoring with Alivecor(®) KardiaMobile and triweekly text messages for 6 months. The primary outcome was use of Alivecor(®) categorized as: infrequent (≤5 times/week), moderate (>5 times and ≤11 times/week), and frequent (>11 times/week). We applied multinomial logistic regression modelling to characterize frequency and predictors of use. Of the 105 participants, 25% were female, 75% were White, and 45% were ≥65 years of age. Premature atrial contractions (PACs) [adjusted odds ratio (OR): 1.23, 1.08–1.40, P = 0.002] predicted frequent as compared to infrequent use. PACs (adjusted OR: 1.17, 95% confidence interval 1.06–1.30, P = 0.003), lower symptom burden (adjusted OR: 1.06, 1.01–1.11, P = 0.02), and less treatment concern (adjusted OR: 0.96, 0.93–0.99, P = 0.02) predicted moderate as compared to infrequent use. CONCLUSIONS: Frequent use of AliveCor(®) is associated with AF symptoms and potentially symptomatic cardiac events. Symptom burden and frequency should be measured and incorporated into analyses of future digital health trials for AF management. |
format | Online Article Text |
id | pubmed-8560656 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-85606562022-03-04 Cardiac symptom burden and arrhythmia recurrence drives digital health use: results from the iHEART randomized controlled trial Masterson Creber, Ruth M Reading Turchioe, Meghan Biviano, Angelo Caceres, Billy Garan, Hasan Goldenthal, Isaac Koleck, Theresa Mitha, Shazia Hickey, Kathleen Bakken, Suzanne Eur J Cardiovasc Nurs Original Articles AIMS: Digital health can transform the management of atrial fibrillation (AF) and enable patients to take a central role in detecting symptoms and self-managing AF. There is a gap in understanding factors that support sustained use of digital health tools for patients with AF. This study identified predictors of Alivecor(®) KardiaMobile ECG monitor usage among patients with AF enrolled in the iPhone(®)Helping Evaluate Atrial fibrillation Rhythm through Technology (iHEART) randomized controlled trial. METHODS AND RESULTS: We analysed data from 105 English and Spanish-speaking adults with AF enrolled in the intervention arm of the iHEART trial. The iHEART intervention included smartphone-based electrocardiogram self-monitoring with Alivecor(®) KardiaMobile and triweekly text messages for 6 months. The primary outcome was use of Alivecor(®) categorized as: infrequent (≤5 times/week), moderate (>5 times and ≤11 times/week), and frequent (>11 times/week). We applied multinomial logistic regression modelling to characterize frequency and predictors of use. Of the 105 participants, 25% were female, 75% were White, and 45% were ≥65 years of age. Premature atrial contractions (PACs) [adjusted odds ratio (OR): 1.23, 1.08–1.40, P = 0.002] predicted frequent as compared to infrequent use. PACs (adjusted OR: 1.17, 95% confidence interval 1.06–1.30, P = 0.003), lower symptom burden (adjusted OR: 1.06, 1.01–1.11, P = 0.02), and less treatment concern (adjusted OR: 0.96, 0.93–0.99, P = 0.02) predicted moderate as compared to infrequent use. CONCLUSIONS: Frequent use of AliveCor(®) is associated with AF symptoms and potentially symptomatic cardiac events. Symptom burden and frequency should be measured and incorporated into analyses of future digital health trials for AF management. Oxford University Press 2021-05-02 /pmc/articles/PMC8560656/ /pubmed/34009326 http://dx.doi.org/10.1093/eurjcn/zvab009 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Articles Masterson Creber, Ruth M Reading Turchioe, Meghan Biviano, Angelo Caceres, Billy Garan, Hasan Goldenthal, Isaac Koleck, Theresa Mitha, Shazia Hickey, Kathleen Bakken, Suzanne Cardiac symptom burden and arrhythmia recurrence drives digital health use: results from the iHEART randomized controlled trial |
title | Cardiac symptom burden and arrhythmia recurrence drives digital health use: results from the iHEART randomized controlled trial |
title_full | Cardiac symptom burden and arrhythmia recurrence drives digital health use: results from the iHEART randomized controlled trial |
title_fullStr | Cardiac symptom burden and arrhythmia recurrence drives digital health use: results from the iHEART randomized controlled trial |
title_full_unstemmed | Cardiac symptom burden and arrhythmia recurrence drives digital health use: results from the iHEART randomized controlled trial |
title_short | Cardiac symptom burden and arrhythmia recurrence drives digital health use: results from the iHEART randomized controlled trial |
title_sort | cardiac symptom burden and arrhythmia recurrence drives digital health use: results from the iheart randomized controlled trial |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560656/ https://www.ncbi.nlm.nih.gov/pubmed/34009326 http://dx.doi.org/10.1093/eurjcn/zvab009 |
work_keys_str_mv | AT mastersoncreberruthm cardiacsymptomburdenandarrhythmiarecurrencedrivesdigitalhealthuseresultsfromtheiheartrandomizedcontrolledtrial AT readingturchioemeghan cardiacsymptomburdenandarrhythmiarecurrencedrivesdigitalhealthuseresultsfromtheiheartrandomizedcontrolledtrial AT bivianoangelo cardiacsymptomburdenandarrhythmiarecurrencedrivesdigitalhealthuseresultsfromtheiheartrandomizedcontrolledtrial AT caceresbilly cardiacsymptomburdenandarrhythmiarecurrencedrivesdigitalhealthuseresultsfromtheiheartrandomizedcontrolledtrial AT garanhasan cardiacsymptomburdenandarrhythmiarecurrencedrivesdigitalhealthuseresultsfromtheiheartrandomizedcontrolledtrial AT goldenthalisaac cardiacsymptomburdenandarrhythmiarecurrencedrivesdigitalhealthuseresultsfromtheiheartrandomizedcontrolledtrial AT kolecktheresa cardiacsymptomburdenandarrhythmiarecurrencedrivesdigitalhealthuseresultsfromtheiheartrandomizedcontrolledtrial AT mithashazia cardiacsymptomburdenandarrhythmiarecurrencedrivesdigitalhealthuseresultsfromtheiheartrandomizedcontrolledtrial AT hickeykathleen cardiacsymptomburdenandarrhythmiarecurrencedrivesdigitalhealthuseresultsfromtheiheartrandomizedcontrolledtrial AT bakkensuzanne cardiacsymptomburdenandarrhythmiarecurrencedrivesdigitalhealthuseresultsfromtheiheartrandomizedcontrolledtrial |